TNFRSF11A

Across TCGA pan-cancer cohorts, TNFRSF11A Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TNFRSF11A data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher TNFRSF11A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TNFRSF11A expression acts as an unfavorable survival marker.

ESCA, SCLC, and PRAD are the cancer types where TNFRSF11A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.080	0.533	<.001	18	view →
SCLC	DFS	Median	All	0.155	0.582	.002	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	OS	Median	All	0.217	0.633	.045	4	view →
KIRP	OS	Median	All	0.635	0.903	.034	3	view →
SKCM	OS	Median	All	0.333	0.780	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TNFRSF11A–ESCA (DFS)

Open the ESCA breakdown →